Who is sponsoring NCT00860704?

NCT00860704 is sponsored by Medical University of Vienna.

What drugs are being tested in NCT00860704?

Interventions in NCT00860704: fluidotherapy with ringer-lactate.

What condition does NCT00860704 study?

NCT00860704 studies Goal Directed Fluid Therapy.

Is NCT00860704 still recruiting?

NCT00860704 is currently completed. Last updated 17 October 2018.

Last reviewed 2018-10-17 · How we verify

NCT00860704: FLO1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intraoperative Goal Directed Fluid Therapy in Lean and Obese Patients

Completed Phase 4 Last updated 17 October 2018

What this trial tests

Phase 4 trial testing fluidotherapy with ringer-lactate in Goal Directed Fluid Therapy in 90 participants. Completed in 1 December 2012.

Timeline

1 November 2007

Primary endpoint
1 December 2012

1 December 2012

Quick facts

Lead sponsor	Medical University of Vienna
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	90
Start date	1 November 2007
Primary completion	1 December 2012
Estimated completion	1 December 2012
Sites	1 location across Austria

Drugs / interventions tested

fluidotherapy with ringer-lactate — full drug profile →

Conditions studied

Goal Directed Fluid Therapy — all drugs for Goal Directed Fluid Therapy →

Sponsor

Medical University of Vienna

Who can join

Adults 18 to 80, female only, with Goal Directed Fluid Therapy. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

different hemodynamic fluid responses in the different groups
Time frame: every 10 minutes during surgery

Sponsor's own description

Intraoperative fluid demand will be monitored by Esophageal Doppler in lean and obese patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Medical University of Vienna trials

Trials by the same sponsor.

NCT07473401 — Retinal Oxygen Metabolism in Children With Myopia · not yet recruiting
NCT07511400 — The Role of NaV1.8 in Human Pain Models · EARLY_PHASE1 · not yet recruiting
NCT07516990 — Intramuscular Injection of Mashed Parathyroid Tissue Into a Forearm During Thyroid Surgery to Prevent Permanent Postoper · NA · recruiting
NCT07496437 — Is Cross-linked Hyaluronic Acid a Biologic Alternative for Alveolar Ridge Preservation? · NA · not yet recruiting
NCT07290712 — Post-Intensive Care Syndrome - Multicentre Prospective Registry Database of the DACH Region · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00860704 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of Vienna
Last refreshed: 17 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00860704.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing